Exclusive: Aviv Regev talks three years of leading Genentech’s research, the future of AI, and not making Nobel predictions

SOUTH SAN FRAN­CIS­CO — In 2020, Aviv Regev end­ed an es­teemed 14-year run at the Broad In­sti­tute to jump in­to the drug in­dus­try, be­com­ing Genen­tech’s head of re­search and ear­ly de­vel­op­ment.

The 52-year-old com­pu­ta­tion­al bi­ol­o­gist has pi­o­neered the field of sin­gle-cell ge­nomics, which stud­ies in­di­vid­ual cells at mas­sive scale, weav­ing to­geth­er bi­ol­o­gy and com­put­er sci­ence. Now, Regev is build­ing what she calls the “lab in a loop” at Genen­tech, where ex­per­i­men­tal and com­pu­ta­tion­al sci­en­tists train and work along­side each oth­er.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.